Key Takeaways
- Niemann-Pick Disease Type C patients will now have access to AQNEURSA™, the first FDA-approved stand-alone therapy for this rare genetic disorder, through Curant Health as the exclusive specialty pharmacy.
- AQNEURSA™ offers significant improvements in neurological symptoms and functional outcomes for both adult and pediatric patients with Niemann-Pick Disease Type C, a condition characterized by progressive neurological decline.
- Curant Health’s partnership with IntraBio underscores its commitment to providing life-changing therapies for rare diseases, offering comprehensive patient support and care management to improve health outcomes.
Curant Health, a leader in providing specialty pharmacy services for rare and complex diseases, has been chosen by IntraBio as the exclusive specialty pharmacy for AQNEURSA™ (levacetylleucine) for Niemann-Pick Disease. AQNEURSA™ is the first Food and Drug Administration (FDA)-approved stand-alone therapy for Niemann-Pick Disease Type C (NPC), a rare genetic disorder that causes progressive neurological deterioration due to a disruption in cholesterol metabolism. This partnership marks a pivotal advancement in the management of NPC, offering new hope for patients who have long faced limited treatment options.
Niemann-Pick Disease Type C is a life-threatening condition that affects approximately 1 in 100,000 live births, leading to significant challenges in managing symptoms and quality of life. NPC is characterized by progressive neurological decline, affecting cognitive function, mobility, speech, and swallowing. Until now, treatment options for NPC have been limited, with few therapies available to address the root causes of the disease. AQNEURSA™ represents a breakthrough in this area, providing a novel approach to managing the neurological symptoms associated with NPC and improving functional outcomes for both adult and pediatric patients.
Curant Health’s role as the exclusive specialty pharmacy for AQNEURSA™ demonstrates the company’s commitment to delivering innovative, life-changing therapies to patients with rare and ultra-rare diseases. As part of this partnership, Curant Health will provide comprehensive support services to ensure that NPC patients receive the care they need throughout their treatment journey. These services include personalized care management, clinical support, and coordination with healthcare providers to optimize treatment outcomes and improve the quality of life for patients and their families.
Curant Health Partners with IntraBio to Provide Life-Changing Therapy for Niemann-Pick Disease Type C Patients
Patrick Dunham, CEO and Co-Founder of Curant Health, expressed his excitement about the new partnership: “Curant Health’s partnership with IntraBio to deliver this new innovative therapy highlights our shared commitment to providing life-changing therapies and support to patients with rare and ultra-rare diseases. We are honored to begin supporting NPC patients and their families along their healthcare journey, and I’m confident our continued dedication and comprehensive end-to-end solution will result in improved quality of life for our NPC patients.”
AQNEURSA™ has shown significant improvements in neurological function, motor skills, and overall patient outcomes in clinical trials. The drug addresses the underlying causes of the disease by targeting the metabolic dysfunction that leads to cholesterol buildup in the cells, which ultimately causes damage to the nervous system. With the approval of AQNEURSA™, patients and their families now have access to a much-needed treatment option that can slow disease progression and provide meaningful improvements in daily functioning.
Curant Health’s exclusive partnership with IntraBio to distribute AQNEURSA™ further solidifies the company’s role as a trusted provider of specialty pharmacy services for rare diseases. By offering tailored care plans and direct support to patients, Curant Health ensures that those living with NPC receive the best possible care, from diagnosis to treatment management.
Curant Health and IntraBio Partnership Advances Rare Disease Care for Niemann-Pick Disease Type C
This collaboration is a significant milestone in the fight against rare diseases and underscores the importance of access to specialized care for patients facing these life-altering conditions. For Curant Health, the partnership reflects its broader mission of improving health outcomes for individuals with complex and chronic conditions through personalized patient care, innovative therapies, and comprehensive support services.
Through this partnership with IntraBio, Curant Health is not only delivering AQNEURSA™ to patients but also providing a range of support services, including medication management, adherence support, and patient education. This approach ensures that patients and their families receive continuous care and guidance throughout their treatment, helping to alleviate the burden of managing a rare disease like NPC.
Curant Health’s commitment to providing life-saving therapies for rare diseases, combined with its patient-centric care model, highlights the company’s role as a key player in the rare disease community. This partnership with IntraBio will make a meaningful impact on the lives of patients and families affected by Niemann-Pick Disease Type C, offering new hope and improved quality of life through access to groundbreaking treatment options like AQNEURSA™.
Resource: Curant Health, September 30, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
